



**CHEP**

1<sup>st</sup> World Congress on

**CONTROVERSIES IN THE  
MANAGEMENT OF VIRAL HEPATITIS**



**BARCELONA • SPAIN • MAY 19-22, 2011**

*Second*  
**ANNOUNCEMENT**



Last update: March 9, 2011

Endorsed by



THE AGA INSTITUTE

[www.comtecmed.com/chep](http://www.comtecmed.com/chep) | [chep@comtecmed.com](mailto:chep@comtecmed.com)

# *Dear Friends and Colleagues,*

The field of Viral Hepatitis is experiencing vast expansion in clinical trials and basic research, as well as in emerging cutting-edge technology. Exciting new drugs are soon becoming available.

**The 1<sup>st</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep)** will function as a comprehensive forum where international experts share and debate state-of-the-art management issues, such as appropriate use of new drugs, in order to outline the optimal treatment for patients.

This innovative Congress is unique in its explicit focus on resolving controversies related to clinical management and treatment of patients infected with viral hepatitis. Controversies raised by recent advances in Hepatitis care will be addressed throughout the comprehensive meeting.

Participants will have the advantage of discussing and debating these unresolved issues with leading world experts in all fields of Viral Hepatitis. Allowing ample time for speaker-audience discussion, the Congress aims at reaching up-to-date and agreed-upon answers to ongoing debates, even when data remains limited, through evidence-based medicine and expert opinion.

We invite you to take part in the **1<sup>st</sup> C-Hep Congress** which is intended as the inaugural event of annual future editions.

*We look forward to an exciting academic event in the beautiful city of Barcelona.*

**Jürgen Rockstroh MD | Jonathan M. Schapiro MD**  
Co-Chairpersons



**Jürgen Rockstroh, MD**  
Germany  
Congress Chairman

**Jonathan M. Schapiro, MD**  
Israel  
Congress Chairman

**Stefan Zeuzem, MD**  
Germany  
HCV Program Director

**Rafael Esteban, MD**  
Spain  
Honorary Opening Lecture

**Fabien Zoulim, MD**  
France  
HBV Program Director

## SCIENTIFIC COMMITTEE

**Alfredo Alberti, Italy**  
*University of Padua*

**Bonaventura Clotet, Spain**  
*HIV Unit and Irsicaixa Foundation, University Hospital "Germans Trias i Pujol", Badalona, Catalonia*

**Greg Dore, Australia**  
*The National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales*

**Geoffrey Dusheiko, UK**  
*UCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London*

**Rafael Esteban, Spain**  
*Vall d'Hebron University Hospital*

**Stephen Locarnini, Australia**  
*Victorian Infectious Diseases Reference Laboratory (VIDRL)*

**Patrick Marcellin, France**  
*Hôpital Beaujon, Clichy*

**Stefan Mauss, Germany**  
*Center for HIV and Hepatogastroenterology, Duesseldorf*

**David R. Nelson, USA**  
*University of Florida College of Medicine*

**George Papatheodoridis, Greece**  
*Athens University Medical School*

**Lars Peters, Denmark**  
*Copenhagen HIV Programme, University of Copenhagen*

**Marion Peters, USA**  
*Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco*

**Vicente Soriano, Spain**  
*Hospital Carlos III, Madrid*

**Mark Sulkowski, USA**  
*Johns Hopkins University School of Medicine*

**Hans L. Tillmann, USA**  
*Duke Clinical Research Institute*

**Heiner Wedemeyer, Germany**  
*Hannover Medical School*

**Cihan Yurdaydin, Turkey**  
*Ankara University Faculty of Medicine*

**Stefan Zeuzem, Germany**  
*J.W. Goethe University Hospital, Frankfurt*

**Fabien Zoulim, France**  
*INSERM Unit 871, Lyon University, and Hospices Civils de Lyon, Lyon*

## FACULTY

**Thomas Berg, Germany**  
*Medical Department Hepatology and Gastroenterology, Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin*

**Charles Boucher, The Netherlands**  
*Erasmus Medical Center, Univ. Rotterdam*

**Raffaele Bruno, Italy**  
*Division Infectious and Tropical Diseases, University of Pavia-Foundation IRCCS San Matteo Hospital*

**Maria Buti, Spain**  
*Hospital Valle Hebron, Barcelona*

**Douglas T. Dieterich, USA**  
*Professor of Medicine, Mount Sinai School of Medicine, New York*

**Greg Dore, Australia**  
*The National Centre in HIV Epidemiology and Clinical Research (NCHECR), University of New South Wales*

**Geoffrey Dusheiko, UK**  
*UCL Centre for Hepatology, University College London Medical School, and Royal Free Hospital, London*

**Rafael Esteban, Spain**  
*Vall d'Hebron University Hospital*

**Xavier Forns, Spain**  
*Liver Unit, Hospital Clinic, Barcelona*

**Brian Gazzard, UK**  
*HIV & Genitourinary Medicine Unit, Kobler Centre, Chelsea and Westminster Hospital*

**Paul Y. Kwo, USA**  
*Indiana University School of Medicine, Indianapolis*

**Pietro Lampertico, Italy**  
*1st Gastroenterology Unit Fondazione Policlinico, Mangiagalli e Regina Elena, University of Milan*

**Michael P. Manns, Germany**  
*Department of Gastroenterology, Hepatology and Endocrinology, Medical School of Hannover*

**Patrick Marcellin, France**  
*Hôpital Beaujon, Clichy*

**Stefan Mauss, Germany**  
*Center for HIV and Hepatogastroenterology, Duesseldorf*

**David R. Nelson, USA**  
*University of Florida College of Medicine*

**Mark Nelson, UK**  
*Chelsea and Westminster Hospital, London*

**Jean Michel Pawlotsky, France**  
*Department of Virology, Henri Mondor Hospital, University of Paris*

**Lars Peters, Denmark**  
*Copenhagen HIV Programme, University of Copenhagen*

**Marion Peters, USA**  
*Chief of Hepatology Research, Division of Gastroenterology, University of California, San Francisco*

**Thierry Poynard, France**  
*Service d'Hepato-Gastroenterologie, Groupe Hospitalier Pitie-Salpetriere, Paris*

**Massimo Puoti, Italy**  
*Malattie Infettive/Infectious Diseases Dept. AO Ospedale Niguarda Cà Granda*

**Andre Rauch, Switzerland**  
*Division of Infectious Diseases, University Hospital Bern and University of Bern*

**Jürgen Rockstroh, Germany**  
*Department of Medicine, University Hospital Bonn*

**Christoph Sarrazin, Germany**  
*J.W. Goethe-University Hospital Frankfurt*

**Jonathan M. Schapiro, Israel**  
*National Hemophilia Center, Sheba Medical Center*

**Kenneth E Sherman, USA**  
*University of Cincinnati College of Medicine*

**Vicente Soriano, Spain**  
*Hospital Carlos III, Madrid*

**Ulrich Spengler, Germany**  
*Professor for Hepatology, Department of Medicine, University Hospital Bonn*

**Hans L. Tillmann, USA**  
*Duke Clinical Research Institute*

**Martin Vogel, Germany**  
*Department of Medicine III, University of Bonn*

**Heiner Wedemeyer, Germany**  
*Hannover Medical School*

**Cihan Yurdaydin, Turkey**  
*Ankara University Faculty of Medicine*

**Stefan Zeuzem, Germany**  
*J.W. Goethe University Hospital, Frankfurt*

**Fabien Zoulim, France**  
*INSERM Unit 871, Lyon University, and Hospices Civils de Lyon*

# PRELIMINARY SCIENTIFIC PROGRAM

## THURSDAY, MAY 19, 2011

<b>Opening Session</b> <b>17:30-18:30</b> <b>Hall A</b>	Welcome Remarks Honorary Opening Lecture: Who has Hepatitis C in 2011? <b>Rafael Esteban</b> , Spain Hepatitis B: Any controversies left? <b>Greg Dore</b> , Australia
<b>18:30-20:00</b>	Welcome Reception

## FRIDAY, MAY 20, 2011

<b>Plenary Session 1</b> <b>8:30-10:00</b> <b>Hall A</b>	Chairpersons Welcome Address HCV Program Director: <b>Stefan Zeuzem</b> , Germany Moderators: <b>Stefan Zeuzem</b> , Germany, <b>Rafael Esteban</b> , Spain  <b>DIRECT ANTIVIRALS: THE FUTURE IS NOW</b> HCV Direct Acting Antivirals: Who are they? <b>Christoph Sarrazin</b> , Germany Who needs them? <b>David Nelson</b> , USA How to use them? <b>Paul Kwo</b> , USA
--	---

10:00-10:30

*Coffee Break*

<b>Plenary Session 2</b> <b>10:30-12:00</b> <b>Hall A</b>	<b>FIRST LINE THERAPY: ARE THERE PREFERRED OPTIONS?</b> Moderators: <b>Stefan Zeuzem</b> , Germany, <b>Rafael Esteban</b> , Spain HCV Protease inhibitors: Overview of a new class of HCV drugs PEG-IFN $\alpha$ 2a vs. PEG-IFN $\alpha$ 2b vs. New Interferons PEG-IFN $\alpha$ 2a: <b>Stefan Zeuzem</b> , Germany PEG-IFN $\alpha$ 2b: <b>Rafael Esteban</b> , Spain New Interferons: <b>Douglas Dieterich</b> , USA
---	--

12:00-13:15

**JANSSEN SYMPOSIUM****WHY DAAS WILL MAKE A DIFFERENCE:  
A NEW HCV TREATMENT ERA**

Welcome and introduction

**Xavier Forns**

Why DAAs will make a difference: efficacy and safety in treatment-naïve patients with HCV

**Xavier Forns**

How will previously treated patients benefit in the new HCV treatment era?

**Graham Foster**

How will drug-drug interactions with DAAs affect patient management?

**Rolf van Heeswijk**

Does resistance matter? Understanding the mechanisms and implications

**Christoph Sarrazin**

Summary and key learnings

**Xavier Forns**

13:15-14:00

*Lunch Break*

<b>Plenary Session 3</b> <b>14:00-15:00</b> <b>Hall A</b>	<b>LIVER BIOPSIES: END OF THE GAME?</b> Moderator: <b>Charles Boucher</b> , The Netherlands New diagnostics for evaluating the liver, first line: <b>Thierry Poynard</b> , France New diagnostics for evaluating the virus: <b>Jean Michel Pawlotsky</b> , France
<b>Session 4</b> <b>15:00-16:00</b> <b>Hall A</b>	Is there still a need for liver biopsies? Yes: <b>Kenneth Sherman</b> , USA No: <b>Thierry Poynard</b> , France
<b>Session 5</b> <b>15:00-16:00</b> <b>Hall B</b>	Does drug resistance testing have a clinical role in HCV therapy? Moderator: <b>Jonathan Schapiro</b> , Israel Pro: <b>Charles Boucher</b> , The Netherlands Con: <b>Jean Michel Pawlotsky</b> , France

# PRELIMINARY SCIENTIFIC PROGRAM

## FRIDAY, MAY 20, 2011

**Session 6**  
**15:00-16:00**  
**Hall C**  
 Frequent viral load monitoring: Necessity or Luxury?  
 Necessity: **Vincente Soriano**, Spain  
 Luxury: **Hans Tillmann**, USA

**16:00-16:30**

*Coffee Break*

**Session 7**  
**16:30-17:30**  
**Session 7A Hall A**  
**Session 7B Hall B**  
**Session 7C Hall C**  
**Clinical Cases**  
**TREATMENT OF HEPATITIS C**  
 Case 1: **Raffaele Bruno**, Italy  
 Case 2: **Lars Peters**, Denmark  
 Case 3: **Xavier Fornis**, Spain

## SATURDAY, MAY 21, 2011

**Session 8**  
**9:00-10:00**  
**Hall A**  
 HIV/HCV Co-infected Patients: Time to treat or time to wait?  
 Treat: **Stefan Mauss**, Germany  
 Wait: **Brian Gazzard**, UK

**Session 9**  
**9:00-10:00**  
**Hall B**  
 Incorporating genetic markers into routine clinical care: Now or Later?  
 Moderator: **Hans Tillmann**, USA  
 Now: **Andre Rauch**, Switzerland  
 Later: **Ulrich Spengler**, Germany

**Session 10**  
**9:00-10:00**  
**Hall C**  
**ACUTE HEPATITIS C: WHAT IS NEW?**  
 Moderator: **Jürgen Rockstroh**, Germany  
 Do we need ribavirin for treatment of acute hepatitis C in HIV coinfecting patients?  
 Yes: **Mark Nelson**, UK  
 No: **Martin Vogel**, Germany

**10:00-10:30**

*Coffee Break*

**Plenary Session 11**  
**10:30-12:00**  
**Hall A**  
**HBV THERAPY IN 2011**  
 HBV Program Director: **Fabien Zoulim**, France  
 Moderator: **Fabien Zoulim**, France, **Maria Buti**, Spain  
 Hepatitis B therapy: **Pietro Lampertico**, Italy  
 Is Hepatitis B curable? **Fabien Zoulim**, France  
 Interferon or oral anti-HBV drugs for first line therapy?  
 Interferon: **Patrick Marcellin**, France  
 Oral anti-HBV drugs: **Maria Buti**, Spain

**12:00-13:15**

**INDUSTRIAL SYMPOSIUM**  
**UNLOCKING NEW POSSIBILITIES IN THE TREATMENT OF HCV G1: THE FUTURE OF DIRECT ACTING ANTIVIRALS**  
*Sponsored by MSD*

**13:15-14:00**

*Lunch Break*

**Plenary Session 12**  
**14:00-15:00**  
**Hall A**  
**CLINICAL CASES: HEPATITIS B**  
*Supported by an unrestricted grant from Gilead*  
 Moderator: **Fabien Zoulim**, France  
**Thomas Berg**, Germany, **Maria Buti**, Spain, **Geoffrey Dusheiko**, UK

**Plenary Session 13**  
**15:00-16:00**  
**Hall A**  
**HOT TOPICS IN VIRAL HEPATITIS**  
 Moderators: **Douglas Dieterich**, USA, **Massimo Puoti**, Italy  
 Treatment of hepatitis Delta: **Heiner Wedemeyer**, Germany  
 Treatment of hepatitis B in pregnancy: **Cihan Yurdaydin**, Turkey  
 Silybinin rescue therapy: **Thomas Berg**, Germany

**16:00-16:30**

*Coffee Break*

**16:30-17:30**

**"PIPELINE SHOWCASE"**  
 Moderator: **Jonathan Schapiro**, Israel  
*Details to be announced soon*

# PRELIMINARY SCIENTIFIC PROGRAM

**SUNDAY, MAY 22, 2011**

**Plenary Session 14**  
**9:00-10:30**  
**Hall A**

## **MANAGEMENT OF ESLD**

Moderators: **Heiner Wedemeyer**, Germany, **Marion Peters**, USA  
 Treatment of HCC: What is new? **Massimo Puoti**, Italy  
 Portal hypertension: State of the art **Ulrich Spengler**, Germany  
 Liver Transplantation in 2011: **Marion Peters**, USA

**10:30-11:00**

*Coffee Break*

**Plenary Session 15**  
**11:00-12:30**  
**Hall A**

## **BEYOND THE HORIZON**

Can HCV be cured without interferon?  
 Yes: **Heiner Wedemeyer**, Germany  
 No: **Geoffrey Duscheiko**, UK  
 The Future is Now: **Michael Manns**, Germany

## YOUNG INVESTIGATORS POSTERS

**SPONSORED BY ROCHE**



We are delighted to provide a special publication opportunity to Young Investigators under the age of 40: the C-Hep Young Investigator Poster Exhibition.

The three Young Investigator Posters with the greatest impact will be awarded with a prize of €250, €500 and €750, respectively.

In addition, 15 Young Investigators will be selected for a participation grant. This grant, sponsored by Roche, will include full registration to the C-Hep Congress, accommodation and partial travel grant.

If you are interested, please submit your important scientific insights into Hepatitis research using the submission form. All posters will be reviewed and assessed by the Congress Scientific Review Committee based on scientific content and impact. The Scientific Review Committee reserves the right to decide on the status of your poster. Successful posters will be placed on a specific poster board at the Congress and published on the Congress website.\*

\* Posters not selected for the participation grant or award will be allocated a poster board only on receipt of registration fees in full. These posters will be published on the Congress website following the Congress, pending receipt of PDF version of poster.

**DEADLINE FOR SUBMISSION: MARCH 18, 2011**

# GENERAL INFORMATION

## DATES

May 19-22, 2011

## VENUE

Palau de Congressos de Catalunya  
Av. Diagonal, 661-671  
Barcelona 08028, Spain  
Tel: +34 93 364 4400  
Fax: +34 93 364 4401  
Website: [www.pcongresos.com](http://www.pcongresos.com)

## REGISTRATION FEES

	Early Registration Until March 1, 2011	Late Registration from March 2 until May 10, 2011	From May 11, 2011 and On Site
Participants - Physicians and Scientists	€540	€590	€650
Residents, Nurses, Students	€385	€430	€470
Accompanying Persons		€140	

Registration fees include: Participation in scientific sessions, Congress bag, program and abstract book, all printed material of the Congress, invitation to the Welcome Reception, coffee breaks, lunch on Friday and Saturday.

## ACCOMMODATION

ComtecMed is the official travel agent for The 1<sup>st</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep) and will offer specially reduced rates for the Congress participants.

Hotel	Category	Single Room	Double Room	Distance from Congress Venue
<b>Rey Juan Carlos Hotel</b>	5 Star Congress Center Hotel	€190	€206	Congress Headquarters Hotel
<b>Husa IIIa</b>	4 Star	€126	€136	15 minutes walk
<b>Senator</b>	4 Star	€113	€126	15 minutes walk

Rates quoted are per room, per night, including breakfast and VAT (8%). Additional hotels in different categories are available upon request.

## CONGRESS SECRETARIAT

Please do not hesitate to contact the Congress Secretariat if you require any additional information or assistance. Please address all correspondence to: [chep@comtecmed.com](mailto:chep@comtecmed.com)

## LIABILITY AND INSURANCE

The Congress Secretariat and Organizers will not accept liability for personal accidents, nor for loss of, or damage to private property of participants, either during or directly arising from the 1<sup>st</sup> World Congress on Controversies in the Management of Viral Hepatitis (C-Hep). Participants should make their own arrangements with respect to health and travel insurance.



**comtecMED**  
MEDICAL CONGRESSES

[www.comtecmed.com/chep](http://www.comtecmed.com/chep)  
[chep@comtecmed.com](mailto:chep@comtecmed.com)

### Headquarters and Administration:

53 Rothschild Boulevard,  
PO Box 68,  
Tel Aviv 61000, Israel  
Tel: +972-3-5666166  
Fax: +972-3-5666177  
Email: [info@comtecmed.com](mailto:info@comtecmed.com)

### Comtec Spain:

Bailén, 95-97,  
pral. 1. a - 08009  
Barcelona, Spain  
Tel: +34-93-2081145  
Fax: +34-93-4579291  
Email: [spain@comtecmed.com](mailto:spain@comtecmed.com)

### Comtec China:

175 Xiang Yang Road South,  
Shanghai 200031  
China  
Tel: +86-21-54660460  
Fax: +86-21-54660450  
Email: [china@comtecmed.com](mailto:china@comtecmed.com)

## SPONSORS (preliminary list)



**comtecMED**  
MEDICAL CONGRESSES

[www.comtecmed.com/chep](http://www.comtecmed.com/chep)  
[chep@comtecmed.com](mailto:chep@comtecmed.com)